Stock movers: Novo Nordisk, Fresenius Medical Care, DaVita, Thor Industries

Indonesia Berita Berita

Stock movers: Novo Nordisk, Fresenius Medical Care, DaVita, Thor Industries
Indonesia Berita Terbaru,Indonesia Berita utama
  • 📰 MarketWatch
  • ⏱ Reading Time:
  • 27 sec. here
  • 2 min. at publisher
  • 📊 Quality Score:
  • News: 14%
  • Publisher: 97%

Novo Nordisk, Thor Industries, Silk Road Medical, Fresenius Medical Care, and DaVita all showed stock price movement in pre-market trading

Shares of Thor Industries Inc. THO rose 2% after the RV maker said its board authorized a 7% dividend increase to 48 cents a share.

Novo Nordisk NVO, +1.03% shares jumped 3% as the Danish drugmaker said it ended a trial early due to efficacy of its diabetes drug Ozempic against kidney disease.Shares of Silk Road Medical Inc. SILK, -0.71% dropped 39% after the medical device company’s forecast fell short of Wall Street estimates, and announced its CEO was retiring.

Shares in Fresenius Medical Care FMS, +0.92% dropped 19% and DaVita DVA, +3.14% stock fell 18% on concerns over future dialysis sales in the wake of the Novo Nordisk trial.

Berita ini telah kami rangkum agar Anda dapat membacanya dengan cepat. Jika Anda tertarik dengan beritanya, Anda dapat membaca teks lengkapnya di sini. Baca lebih lajut:

MarketWatch /  🏆 3. in US

Indonesia Berita Terbaru, Indonesia Berita utama

Similar News:Anda juga dapat membaca berita serupa dengan ini yang kami kumpulkan dari sumber berita lain.

HP Inc., Silk Road Medical, Walgreens, Fresenius Medical, Birkenstock, and More Stock Market MoversHP Inc., Silk Road Medical, Walgreens, Fresenius Medical, Birkenstock, and More Stock Market MoversHP Inc. is increasing its annual dividend by 5%, Silk Road Medical reduces full-year revenue guidance, and Birkenstock makes its trading debut Wednesday.
Baca lebih lajut »

Novo Nordisk stops Ozempic kidney trial after early signs of successNovo Nordisk stops Ozempic kidney trial after early signs of successNovo Nordisk (NOVOb.CO) said on Tuesday it will stop a trial studying Ozempic to treat kidney failure in diabetes patients ahead of schedule because it was clear from an interim analysis that the treatment would succeed.
Baca lebih lajut »

How Ozempic and Wegovy turned Novo Nordisk into a $400 billion companyHow Ozempic and Wegovy turned Novo Nordisk into a $400 billion companyHow Ozempic and Wegovy turned Novo Nordisk into a $400 billion company
Baca lebih lajut »

UCSD Health buys Alvarado Hospital Medical Center, makes bid to partner with Tri-City Medical CenterUCSD Health buys Alvarado Hospital Medical Center, makes bid to partner with Tri-City Medical CenterUniversity health system says it needs to ease crowding at its two campuses in La Jolla and Hillcrest
Baca lebih lajut »

Workers launch strike at 4 Prime Healthcare hospitals in Lynwood, Inglewood, Garden Grove and EncinoWorkers launch strike at 4 Prime Healthcare hospitals in Lynwood, Inglewood, Garden Grove and EncinoThe unfair labor practices strike at Prime is impacting operations at St. Francis Medical Center in Lynwood, Centinela Hospital Medical Center in Inglewood, Garden Grove Hospital Medical Center and…
Baca lebih lajut »

Employers Covering Weight-Loss Drugs Could DoubleThe number of U.S. employers who cover obesity medications, including Wegovy from Novo Nordisk that belongs to a class of GLP-1 drugs, could nearly double next year, according to a survey.
Baca lebih lajut »



Render Time: 2025-02-28 10:17:51